Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM |
| December 18, 2020 | December 2020 Bond Updates |
|
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology... |
| View more at: https://www.prnewswire.com:443/news-releases/antengene-announces-approval-of-ind-application-in-china-for-a-phase-3-clinical-trial-of-atg-010-selinexor-in-combination-with-bortezomib-and-dexamethasone-svd-for-the-treatment-of-rrmm-301195807.html |
| Related News |
|